New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Articles|November 25, 2014
- Immunotherapy (Issue 4)
- Volume 4
- Issue 1
Adverse Events Associated With Immunotherapy in Lung Cancer
Author(s)Vassiliki Papadimitrakopoulou, MD
Vassiliki Papadimitrakopoulou, MD, discusses adverse events associated with immunotherapies for the treatment of lung cancer.
Advertisement
Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses adverse events associated with immunotherapies for the treatment of lung cancer.
<<<
Articles in this issue
almost 12 years ago
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Questionalmost 12 years ago
Programs Prepare for Immuno-Oncology in Clinical Settingalmost 12 years ago
Right Patient for Immunotherapy in NSCLC Exploredalmost 12 years ago
Weight May Affect Toxicity of Immunotherapiesalmost 12 years ago
Immunotherapy Potential Option in Mesothelioma Treatmentalmost 12 years ago
Potential Immunotherapies for Head and Neck Cancersalmost 12 years ago
Immunotherapies for Prostate CancerAdvertisement
Related to this article
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5